DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Axelrod L. Perioperative management of patients treated with
glucocorticoids. Endocrinol Metab Clin North Am, 2003,
32:367–383.
Bale TL, Vale W. CRF and CRF receptors: role in stress responsivity
and other behaviors. Annu Rev Pharmacol Toxicol, 2004,
44:525–557.
Bray PJ, Cotton RG. Variations of the human glucocorticoid
receptor gene (NR3C1): pathological and in vitro mutations
and polymorphisms. Hum Mutat, 2003, 21:557–568.
Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent
Cushing’s syndrome: A consensus
statement. J Clin Endocrinol Metab, 2008, 93:2454-2462.
Bracken MB. Steroids for acute spinal cord injury. Cochrane
Database Syst Rev, 2002, CD001046.DOI: 10.1002/
14651858.CD001046.
Carey RM. The changing clinical spectrum of adrenal insufficiency.
Ann Intern Med, 1997, 127:1103–1105.
Chang AY, Ghayee HK, Auchus RJ. Dehydroepiandrosterone
replacement therapy—panacea, snake oil, or a bit of both? Nat
Clin Pract Endocrinol Metab, 2008, 4:442–443.
Charmandari E, Kino T, Ichijo T, Chrousos GP. Generalized glucocorticoid
resistance: Clinical aspects, molecular mechanisms,
and implications of a rare genetic disorder. J Clin
Endocrinol Metab, 2008, 93:1563–1572.
Chrousos GP. The hypothalamic-pituitary-adrenal axis and
immune-mediated inflammation. N Engl J Med, 1995, 332:
1351–1362.
Clark AJ, Metherell LA, Cheetham ME, Huebner A. Inherited
ACTH insensitivity illuminates the mechanisms of ACTH
action. Trends Endocrinol Metab, 2005, 16:451–457.
Coursin DB, Wood KE. Corticosteroid supplementation for adrenal
insufficiency. JAMA, 2002, 287:236–240.
De Bosscher K, Vanden Berghe W, Haegeman G. The interplay
between the glucocorticoid receptor and nuclear factor-kB or
activator protein-1: Molecular mechanisms for gene repression.
Endocr Rev, 2003, 24:488–522.
Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis
Campaign: International guidelines for management of severe
sepsis and septic shock: 2008. Crit Care Med, 2008, 36:296–327.
Derendorf H, Nave R, Drollmann A, et al. Relevance of pharmacokinetics
and pharmacodynamics of inhaled corticosteroids
to asthma. Eur Respir J, 2006, 28:1042–1050.
Derijk RH, van Leeuwen N, Klok MD, Zitman FG.
Corticosteroid receptor-gene variants: Modulators of the
stress-response and implications for mental health. Eur J
Pharmacol, 2008, 585:492–501.
Elenkov IJ, Chrousos GP. Stress system—organization, physiology
and immunoregulation. Neuroimmunomodulation, 2006,
13:257–267.
Farooki IS, Keogh JM, Yeo GSH, et al. Clinical spectrum of obesity
and mutations in the melanocortin 4 receptor gene. N Engl
J Med, 2003, 348:1085–1095.
Farooqi IS, Volders K, Stanhope R, et al. Hyperphagia and earlyonset
obesity due to a novel homozygous missense mutation in
prohormone convertase 1/3. J Clin Endocrinol Metab, 2007,
92:3369–3373.
Gross KL, Cidlowski JA. Tissue-specific glucocorticoid action:
A family affair. Trends Endocrinol Metab, 2008, 19:331–339.
Hammer F, Stewart PM. Cortisol metabolism in hypertension.
Best Pract Res Clin Endocrinol Metab, 2006, 20:337–353.
Hochberg Z, Pacak K, Chrousos GP. Endocrine withdrawal syndromes.
Endocr Rev, 2003, 24:523–538.
Holsboer F, Ising M. Central CRH system in depression and
anxiety—evidence from clinical studies with CRH1 receptor
antagonists. Eur J Pharmacol, 2008, 583:350–357.
Johanssen S, Allolio B. Mifepristone (RU 486) in Cushing’s syndrome.
Eur J Endocrinol, 2007, 157:561–569.
Kraemer FB. Adrenal cholesterol utilization. Mol Cell
Endocrinol, 2007, 265–266:42–45.
Lavery GG, Walker EA, Tiganescu A, et al. Steroid biomarkers
and genetic studies reveal inactivating mutations in hexose-6-
phosphate dehydrogenase in patients with cortisone reductase
deficiency. J Clin Endocrinol Metab, 2008, 93:3827–3832.
Lee YS, Challis BG, Thompson DA, et al. A POMC variant implicates
[beta]-melanocyte-stimulating hormone in the control of
human energy balance. Cell Metabolism, 2006, 3:135–140.
Magiakou MA, Smyrnaki P, Chrousos GP. Hypertension in
Cushing’s syndrome. Best Pract Res Clin Endocrinol Metab,
2006, 20:467–482.
McMaster A, Ray DW. Drug insight: Selective agonists and
antagonists of the glucocorticoid receptor. Nat Clin Pract
Endocrinol Metab, 2008, 4:91–101.
Meier-Kriesche HU, Li S, Gruessner RW, et al.
Immunosuppression: Evolution in practice and trends,
1994–2004. Am J Transplant, 2006, 6:1111–1131.
Mencarrelli M, Walker GE, Maestrini S, et al. Sporadic mutations
in melanocortin receptor 3 in morbid obese individuals.
Eur J Hum Genet, 2008, 16:581–586.
Morgan C, Cone RD. Melanocortin-5 receptor deficiency in
mice blocks a novel pathway influencing pheromone-induced
aggression. Behav Genet, 2006, 36:291–300.
Norman AW, Mizwicki MT, Norman DP. Steroid-hormone rapid
actions, membrane receptors, and a conformational ensemble
model. Nat Rev Drug Discov, 2004, 3:27–41.
Parker KL, Rice DA, Lala DS, et al. Steroidogenic factor 1: An
essential mediator of endocrine development. Rec Prog
Hormone Res, 2002, 57:19–36.
Rambaldi A, Saconato HH, Christensen E, et al. Systematic
review: Glucocorticosteroids for alcoholic hepatitis—a
Cochrane Hepato-Biliary Group systematic review with metaanalyses
and trial sequential analyses of randomized clinical
trials. Aliment Pharmacol Ther, 2008, 27:1167–1178.
Roberts D, Dalziel S. Antenatal corticosteroids for accelerating
fetal lung maturation for women at risk of preterm birth.
Cochrane Database Syst Rev, 2006, 3:CD004454.
Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for
patients with septic shock. N Engl J Med, 2008, 358: 111–124.
Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids.
Nat Clin Pract Rheumatol, 2008, 4:525–533.
Stocco DM. Clinical disorders associated with abnormal cholesterol
transport: Mutations in the steroidogenic acute regulatory
protein. Mol Cell Endocrinol, 2002, 191:19–25.
Surget A, Belzung C. Involvement of vasopressin in affective
disorders. Eur J Pharmacol, 2008, 583:340–349.
Woolf AD. An update on glucocorticoid-induced osteoporosis.
Curr Opin Rheumatol, 2007, 19:370–375.
1235
CHAPTER 42
ACTH, ADRENAL STEROIDS, AND PHARMACOLOGY OF THE ADRENAL CORTEX